

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

**(1) POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING
HELD ON MAY 31, 2024;**
**(2) RE-ELECTION OF DIRECTORS OF THE SECOND
SESSION OF THE BOARD;**
AND
**(3) RE-ELECTION OF SUPERVISORS OF THE SECOND
SESSION OF THE BOARD OF SUPERVISORS**

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”, together with the Circular, the “**AGM Documents**”) of the annual general meeting (the “**2023 AGM**”) of Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 (the “**Company**”) both dated April 26, 2024. Unless the context otherwise requires, the terms used in this announcement shall have the same meaning as those defined in the AGM Documents.

ATTENDANCE AT THE 2023 AGM

The board is pleased to announce that the 2023 AGM was convened and held at 2:00 p.m. on Friday, May 31, 2024 at Meeting Room, 3/F, Block 5, B Area, No. 777 Binhai 4th Road, Hangzhou Bay New Area, Ningbo, Zhejiang Province, PRC. The 2023 AGM was convened by the Board in accordance with the Company Law of the PRC (《中華人民共和國公司法》) and the Articles of Association, and chaired by Mr. LV Shiwen, the Chairman of the Board. All Directors attended the 2023 AGM either in person or by electronic means.

As at the date of the 2023 AGM, the total number of issued Shares was 417,167,290 Shares, comprising 310,306,209 H Shares and 106,861,081 Unlisted Shares. The total number of Shares entitling the Shareholders to attend and vote for or against or abstain from voting on the proposed resolutions at the 2023 AGM was 416,917,290. Shareholders holding a total of 299,317,448 Shares and representing approximately 71.75% of the total number of issued Shares (including their proxies and authorized representatives) attended the 2023 AGM. All the proposed resolutions as set out in the Notice were voted by way of poll at the 2023 AGM.

The holders of a total of 250,000 H Shares as at the opening of business on the date of the 2023 AGM was required to abstain and had abstained from voting on the proposed resolutions at the 2023 AGM pursuant to Rule 17.05A of the Listing Rules and the scheme rules of the H share award scheme of the Company. Save as disclosed herein, to the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the 2023 AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the 2023 AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the 2023 AGM.

POLL RESULTS OF THE 2023 AGM

The poll results of the resolutions proposed at the 2023 AGM are as follows:

Ordinary Resolutions		Number of votes (%)			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the resolution on the report of the Board of Directors of the Company for the year 2023.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
2.	To consider and approve the resolution on the report of the Board of Supervisors of the Company for the year 2023.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
3.	To consider and approve the resolution on the audited consolidated financial statements of the Company for the year 2023.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
4.	To consider and approve the resolution on the annual report of the Group for the year 2023.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
5.	To consider and approve the resolution on the financial accounts report of the Group for the year 2023.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
6.	To consider and approve the resolution on the financial budget of the Group for the year 2024.	299,313,448 (99.998664%)	2,400 (0.000801%)	1,600 (0.000535%)	Yes

Ordinary Resolutions		Number of votes (%)			Passed by Shareholders
		For	Against	Abstain	
7.	To consider and approve the resolution on the annual profit distribution plan of the Company for the year 2023.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
8.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for 2024, for a term commencing from the date of approval at the 2023 AGM until the conclusion of the 2024 annual general meeting of the Company, and authorize the Board to determine the specific matters, including but not limited to their remunerations, in relation to such re-appointment.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
9.	To consider and approve the proposed re-election of Directors of the second session of the Board:				
	(i) Mr. Lv Shiwen as an executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(ii) Mr. Pan Fei as an executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(iii) Mr. Tan Ching as a non-executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(iv) Mr. Zheng Jiaqi as a non-executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(v) Ms. Xie Youpei as a non-executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(vi) Mr. Chen Xinxing as a non-executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(vii) Dr. Lin Shoukang as an independent non-executive Director;	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(viii) Ms. Du Jiliu as an independent non-executive Director; and	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(ix) Dr. Mei Lehe as an independent non-executive Director.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes

Ordinary Resolutions		Number of votes (%)			Passed by Shareholders
		For	Against	Abstain	
10.	To consider and approve the proposed re-election of Supervisors of the second session of the Board of Supervisors:				
	(i) Ms. Xu Jing as a shareholders' representative Supervisor; and	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
	(ii) Mr. Tang Hao as a shareholders' representative Supervisor.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
11.	To determine the remuneration of the Directors.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes
12.	To determine the remuneration of the Supervisors.	299,315,848 (99.999465%)	0 (0.000000%)	1,600 (0.000535%)	Yes

As more than half of the votes were cast in favour of ordinary resolutions numbered 1 to 12 above, all resolutions proposed at the 2023 AGM were duly passed as ordinary resolutions.

RE-ELECTION OF DIRECTORS OF THE SECOND SESSION OF THE BOARD

Mr. Lv Shiwen and Mr. Pan Fei were re-elected as executive Directors of the second session of the Board; Mr. Tan Ching, Mr. Zheng Jiaqi, Ms. Xie Youpei and Mr. Chen Xinxing were re-elected as non-executive Directors of the second session of the Board; and Dr. Lin Shoukang, Ms. Du Jiliu and Dr. Mei Lehe were re-elected as independent non-executive Directors of the second session of the Board at the 2023 AGM.

The biographical details and remuneration of the Directors who were re-elected as Directors of the second session of the Board required to be disclosed under Rule 13.51(2) of the Listing Rules are set out in the Circular. As at the date of this announcement, there has been no change to such information.

The service contract with each of the re-elected Directors has been renewed. The term of office of each of them as a Director of the second session of the Board is for a period commencing from the date of the 2023 AGM to the date of the annual general meeting to be convened in 2027.

RE-ELECTION OF SUPERVISORS OF THE SECOND SESSION OF THE BOARD OF SUPERVISORS

Ms. Xu Jing and Mr. Tang Hao were re-elected as shareholders' representative Supervisors of the second session of the Board of Supervisors at the 2023 AGM. The biographical details and remuneration of Ms. Xu Jing and Mr. Tang Hao required to be disclosed under Rule 13.51(2) of the Listing Rules are set out in the Circular. As at the date of this announcement, there has been no change to such information.

Mr. Hu Bo was elected as the employees' representative Supervisor of the second session of the Board of Supervisors at the employee representatives assembly of the Company held on March 18, 2024. The re-election of Mr. Hu Bo is not subject to the approval by the Shareholders. The biographical details and remuneration of Mr. Hu Bo required to be disclosed under Rule 13.51(2) of the Listing Rules are set out in the 2023 annual report of the Company published on April 26, 2024. As of the date of this announcement, there has been no change to such information.

The service contract with each of the re-elected Supervisors has been renewed. The term of office of each of them as a Supervisor of the second session of the Board of Supervisors is for a period commencing from the date of the 2023 AGM to the date of the annual general meeting to be convened in 2027.

SCRUTINEERS

The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the 2023 AGM. Two representatives of the Shareholders, one lawyer of Commerce & Finance Law Offices and one Supervisor also participated in the scrutiny of the poll results at the 2023 AGM.

By Order of the Board
Jenscare Scientific Co., Ltd.
LV Shiwen
Chairman of the Board

Hong Kong, May 31, 2024

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.